Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

  • STATUS
    Recruiting
  • participants needed
    10
  • sponsor
    Ampio Pharmaceuticals. Inc.
Updated on 19 February 2024
dyspnea
oximetry
covid-19
SARS
oxygen supplementation
acute respiratory syndrome (sars)

Summary

This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who require supplemental oxygen.

Details
Condition Covid 19
Age 18-89 years
Treatment Standard of Care, Ampion
Clinical Study IdentifierNCT04456452
SponsorAmpio Pharmaceuticals. Inc.
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female, 18 years to 89 years old (inclusive)
Hospitalized and diagnosed with COVID-19, as evaluated by PCR test confirming infection with SARS-COV-2
Patient is receiving supplemental oxygen (e.g. oxygen saturation (SpO2) <88%, labored breathing, increased respiratory rate, dyspnea on rest or exertion)
A signed informed consent form from the patient or the patient's legal representative must be available

Exclusion Criteria

In the opinion of the clinical team, progression to death is imminent and inevitable, irrespective of the provision of treatments
Patient has severe chronic obstructive pulmonary disease (COPD), chronic renal failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.)
Patient is on chronic immunosuppressive medication
As a result of the medical review and screening investigation, the Principal Investigator considers the patient unfit for the study
A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)
Patient has known pregnancy or is currently breastfeeding
Participation in another clinical trial
Baseline QT prolongation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.